News
DNLI
19.85
-2.36%
-0.48
Weekly Report: what happened at DNLI last week (1102-1106)?
Weekly Report · 1d ago
Denali Therapeutics (DNLI) Stock Looks Fairly Valued After Recent Gains
Simply Wall St · 4d ago
B. Riley Securities Keeps Their Buy Rating on Denali Therapeutics (DNLI)
TipRanks · 5d ago
Denali Therapeutics Stock Earnings Beat Has The Bull Case Changed?
Simply Wall St · 5d ago
Analysts Offer Insights on Healthcare Companies: Smith & Nephew Snats (SNN), Denali Therapeutics (DNLI) and Oculis Holding (OCS)
TipRanks · 6d ago
Denali Therapeutics Is Maintained at Overweight by Morgan Stanley
Dow Jones · 6d ago
Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $42
Benzinga · 6d ago
Denali (DNLI) Q3 2026 Earnings Call Transcript
The Motley Fool · 6d ago
Denali Therapeutics Is Maintained at Outperform by Wedbush
Dow Jones · 6d ago
Wedbush Maintains Outperform on Denali Therapeutics, Raises Price Target to $24
Benzinga · 6d ago
Cantor Fitzgerald Reaffirms Their Buy Rating on Denali Therapeutics (DNLI)
TipRanks · 6d ago
Denali’s AVLAYAH Momentum and 2027 Clinical Catalysts Support Buy Rating
TipRanks · 6d ago
Denali Therapeutics price target raised to $42 from $40 at Morgan Stanley
TipRanks · 6d ago
Denali Therapeutics price target raised to $24 from $23 at Wedbush
TipRanks · 6d ago
Denali Therapeutics Price Target Maintained With a $39.00/Share by BTIG
Dow Jones · 6d ago
BTIG Reiterates Buy on Denali Therapeutics, Maintains $39 Price Target
Benzinga · 6d ago
Denali Therapeutics (DNLI) Swings To Q3 Profit, Is The Upside Already Priced In?
Simply Wall St · 6d ago
Denali Therapeutics Reports Third Quarter 2026 Financial Results
NASDAQ · 11/03 23:52
UPDATE: Denali Therapeutics Q3 Adj. EPS $(0.64) Misses $(0.53) Estimate, Sales $17.778M Beat $10.657M Estimate
Benzinga · 11/03 23:02
Denali Therapeutics Q3 2026 Earnings Call Transcript
Benzinga · 11/03 22:56
More
Webull provides a variety of real-time DNLI stock news. You can receive the latest news about Denali Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About DNLI
Denali Therapeutics Inc. is a biopharmaceutical company establishing a new class of biotherapeutics designed to cross the blood-brain barrier using its TransportVehicle platform. It is focused on building a portfolio of therapeutic candidates by investing in its TV franchises, i.e., Enzyme TV (ETV), Oligonucleotide TV (OTV), and Antibody TV (ATV), to advance programs for rare diseases, such as lysosomal storage diseases, and common diseases, such as Alzheimer's disease and Parkinson's disease. Its most advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (Hunter syndrome). TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for mucopolysaccharidosis IIIA (Sanfilippo syndrome type A), DNL593 (PTV:PGRN) for frontotemporal dementia-granulin, DNL628 (OTV:MAPT) for Alzheimer’s disease, and DNL952 (ETV:GAA) for Pompe disease. It is also pursuing opportunities in other disease areas including oncology.